

<b>Doravirine (DOR) Interactions</b> (also see drug package inserts)		NYSDOH AI Clinical Guidelines Program   <a href="http://www.hivguidelines.org">www.hivguidelines.org</a>
<b>Class or Drug</b>	<b>Mechanism of Action</b>	<b>Clinical Comments</b>
Strong inducers or inhibitors of CYP3A [Deeks 2018]	DOR is a substrate of CYP3A, and as such, drugs that affect its metabolism affect its concentrations.	<ul style="list-style-type: none"> <li>• Avoid concomitant use if possible.</li> <li>• Dose adjustments of DOR are not recommended.</li> <li>• Consider alternative concomitant agents.</li> </ul>
Carbamazepine, oxcarbazepine, phenobarbital, phenytoin	Coadministration may significantly reduce concentrations of ARV agents through induction of CYP450 system.	<ul style="list-style-type: none"> <li>• Coadministration is not recommended; use alternative anticonvulsant.</li> <li>• If benefit of use outweighs risk, monitor carefully for efficacy and toxicity.</li> <li>• Perform therapeutic drug monitoring if use cannot be avoided.</li> </ul>
<p><b>Abbreviations:</b> ARV, antiretroviral agents; CYP, cytochrome P450.</p> <p><b>No significant interactions/no dose adjustments necessary:</b> Common oral antibiotics; drugs used as antihypertensive agents; anticoagulants; antiplatelet drugs; statins; antidiabetic drugs; polyvalent cations; asthma and allergy medications; long-acting beta agonists; inhaled and injected corticosteroids; antidepressants; benzodiazepines; sleep medications; antipsychotics; non-opioid pain medications; opioid analgesics and tramadol; hormonal contraceptives; erectile and sexual dysfunction agents; tobacco and smoking cessation products; alcohol, disulfiram, and acamprosate; methadone, buprenorphine, naloxone, and naltrexone; immunosuppressants.</p>		

#### Reference

Deeks ED. Doravirine: First global approval. *Drugs* 2018;78(15):1643-1650. [PMID: 30341683] <https://www.ncbi.nlm.nih.gov/pubmed/30341683>